2nd Annual Tissue Engineering & Regenerative Medicine featuring EuropaBio Policy Forum (BALS)

Venue: Crowne Plaza Brussels City Center

Location: Brussels, Belgium

Event Date/Time: Nov 07, 2006 End Date/Time: Nov 08, 2006
Report as Spam


Cell-based therapies are the new trend in regenerative medicine for improving the health and quality of people’s lives worldwide. Today, there are ethical legal and social issues in stem cell research and therapy that affect not only the policy makers but also the public opinion. How big is the potential of clinical application of human cells? Are advanced therapies the answer for successful treatment of neurodegenerative diseases? How far is the stem cell research in therapeutic drug discovery?
This 2nd annual conference on Tissue Engineering & Regenerative Medicine brings together senior representatives from leading specialty companies to discuss effective commercializing strategies of tissue engineered products and advanced therapies. You will get an insider view on what will the future bring for regenerative medicine and stem cell research. The case studies will reveal latest development stages of cell-based therapeutic products and compare the reimbursement policies within EU countries.

EuropaBio Policy Forum
Before Member States vote on the Advanced Therapies Regulation - what issues remain unresolved?
The EuropaBio Policy Forum is to enable companies who are in the hard line of this new emerging area to give views direct to the European decision makers and representatives of the EU institutions who are in charge of regulating Advanced therapies - gene, tissue and cell therapies in Europe. For the fist time, Europe is about to agree the rules governing what is to be one of the largest single markets in the world for these new emerging therapies. How will the rules impact your business? What are the threats and opportunities? Meet the legislators and get your industry concerns across during this Policy Forum before Member States cast their votes.

Key topics:

Commercialization strategies for therapeutics based on living cells
Non-reimbursed products in regenerative medicine
Approaching a stem cell therapy for Parkinson’s Disease
Regulatory challenges affecting Human Tissue Engineered Products
EuropaBio Policy Forum

Key Speakers:
Kelvin Brockbank, President & CSO, Organ Recovery Systems
Patrick Bilbo, Vice president Clinical & Regulatory Affairs, Organogenesis
Duncan MacKay, Head of Regulatory Affairs for TEP in Europe, Genzyme Biosurgery
Johan Ericson, Department of Cell and Molecular Biology, Karolinska Institute
Eric Miljan, Head of Stem Cell Discovery, ReNeuron